Quarterly ResultMay 12, 2026, 05:12 PM
COSCIENS Biopharma Reports Q1 Net Income $10.76M; German Subsidiary Deconsolidation
AI Summary
COSCIENS Biopharma Inc. reported a net income of $10.76 million for Q1 2026, a significant improvement from a net loss of $3.66 million in Q1 2025. This turnaround was primarily driven by a $10.94 million income from discontinued operations following the deconsolidation of its German subsidiaries, which filed for insolvency. Despite the net income, the company's continuing operations incurred a net loss of $0.18 million, and it faces substantial doubt about its ability to continue as a going concern due to sustained revenue decline and negative operating cash flows.
Key Highlights
- Net income for Q1 2026 was $10.76 million, compared to a net loss of $3.66 million in Q1 2025.
- Income from discontinued operations was $10.94 million in Q1 2026, following German subsidiary deconsolidation.
- Net loss from continuing operations was $0.18 million in Q1 2026, down from $2.67 million in Q1 2025.
- Revenues increased to $1.89 million in Q1 2026 from $1.39 million in Q1 2025.
- Basic income per share was $3.42 in Q1 2026, up from a loss of $1.16 in Q1 2025.
- Cash and cash equivalents decreased to $5.01 million as of March 31, 2026, from $7.31 million at Dec 31, 2025.
- Net cash used in operating activities was $(2.18) million in Q1 2026.
- Company faces substantial doubt about its ability to continue as a going concern.
Price Impact
More from CSCIF